

## DAFTAR PUSTAKA

- Anand, S., Burkenroad, A., & Glaspy, J. (2020). Workup of anemia in cancer. *Clinical Advances in Hematology and Oncology*, 18(10), 640–646.
- Brar, G., Greten, T. F., Graubard, B. I., McNeel, T. S., Petrick, J. L., McGlynn, K. A., & Altekruse, S. F. (2020). Hepatocellular Carcinoma Survival by Etiology: A SEER-Medicare Database Analysis. *Hepatology Communications*, 4(10), 1541–1551. <https://doi.org/10.1002/hep4.1564>
- Calderon-Martinez, E., Landazuri-Navas, S., Vilchez, E., Cantu-Hernandez, R., Mosquera-Moscoso, J., Encalada, S., Al lami, Z., Zevallos-Delgado, C., & Cinicola, J. (2023). Prognostic Scores and Survival Rates by Etiology of Hepatocellular Carcinoma: A Review. *Journal of Clinical Medicine Research*, 15(4), 200–207. <https://doi.org/10.14740/jocmr4902>
- De Toni, E. N., Schlesinger-Raab, A., Fuchs, M., Schepp, W., Ehmer, U., Geisler, F., Rieke, J., Paprottka, P., Friess, H., Werner, J., Gerbes, A. L., Mayerle, J., & Engel, J. (2020). Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: A population-based study. *Gut*, 69(1), 168–176. <https://doi.org/10.1136/gutjnl-2018-318193>
- Ding, J., & Wen, Z. (2021). Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. *BMC Cancer*, 21(1), 1–12. <https://doi.org/10.1186/s12885-021-08904-3>
- Effendi, K., Rahadiani, N., Stephanie, M., Kurebayashi, Y., Tsujikawa, H., Jasirwan, C. O. M., Syaiful, R. A., & Sakamoto, M. (2024). Comparative Immunohistochemical Analysis of Clinicopathological Subgroups in Hepatocellular Carcinomas from Japan and Indonesia. *Journal of Clinical and Experimental Hepatology*, 14(6), 101451. <https://doi.org/10.1016/j.jceh.2024.101451>
- Giannini, E. G., Farinati, F., Ciccarese, F., Pecorelli, A., Rapaccini, G. L., Marco, M. Di, Benvegn, L., Caturelli, E., Zoli, M., & Borzio, F. (2014). *Prognosis of Untreated Hepatocellular Carcinoma*. 184–190. <https://doi.org/10.1002/hep.27443>
- Giannitrapani, L., Zerbo, M., Amodeo, S., Pipitone, E., Galia, M., Li Cavoli, T. V., Minissale, M. G., Licata, A., Schiavone, C., Brancatelli, G., Montalto, G., Soresi, M., & Galati, L. (2020). The Changing Epidemiology of Hepatocellular Carcinoma: Experience of a Single Center. *BioMed Research International*, 2020. <https://doi.org/10.1155/2020/5309307>
- Hasan, I., Mangunkusumo, S. C., Loho, I. M., Gastroenterologi, S. M. F., Dharmais, R. S. K., & Nasional, P. K. (2020). *Liver Function and Treatment Modalities are Predictors of Survival in Patients with Hepatocellular Carcinoma Fungsi Hati dan Jenis Terapi Merupakan Prediktor Kesintasan Pasien Karsinoma Sel Hati*. 7(3). <https://doi.org/10.7454/jpdi.v7i3.460>
- Hashimoto, K. (n.d.). (HALP) score is a useful predictor of prognosis after

- hepatectomy for hepatocellular carcinoma : a retrospective , propensity score matching cohort study.* 1–16. Hong, Y. M., Yoon, K. T., Hwang, T. H., & Cho, M. (2020). Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. *BMC Cancer*, 20(1), 1–9. <https://doi.org/10.1186/s12885-020-07105-8>
- Honma, Y., Shibata, M., Ikemi, M., Yoshitomi, K., Shinohara, N., Ogino, N., Oe, S., Miyagawa, K., Abe, S., & Harada, M. (2025). Usefulness of the Early Increase of Peripheral Blood Lymphocyte Count in Predicting Clinical Outcomes for Patients with Advanced Hepatocellular Carcinoma Treated with Durvalumab Plus Tremelimumab. *Cancers*, 17(8), 1–15. <https://doi.org/10.3390/cancers17081274>
- Indriaswati, T. (2024). *Skor albumin bilirubin (albi) sebagai prediktor survival 1 tahun pasien dengan karsinoma hepatoseluler di rsup dr sardjito.*
- Itoh, S., Yugawa, K., Shimokawa, M., Yoshiya, S., Mano, Y., Takeishi, K., Tushima, T., Maehara, Y., Mori, M., & Yoshizumi, T. (2019). Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection. *BJS Open*, 3(4), 500–508. <https://doi.org/10.1002/bjs5.50170>
- Jeng, L. Bin, Chan, W. L., & Teng, C. F. (2023). Prognostic Significance of Serum Albumin Level and Albumin-Based Mono- and Combination Biomarkers in Patients with Hepatocellular Carcinoma. *Cancers*, 15(4). <https://doi.org/10.3390/cancers15041005>
- Jindal, A., Thadi, A., & Shailubhai, K. (2019). Hepatocellular Carcinoma: Etiology and Current and Future Drugs. *Journal of Clinical and Experimental Hepatology*, 9(2), 221–232. <https://doi.org/10.1016/j.jceh.2019.01.004>
- Kong, J. Y., Li, S. M., Fan, H. Y., Zhang, L., Zhao, H. J., & Li, S. M. (2018). Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. *Medicine (United States)*, 97(33), 1–8. <https://doi.org/10.1097/MD.00000000000011872>
- Li, Q., Cao, M., Lei, L., Yang, F., Li, H., Yan, X., He, S., Zhang, S., Teng, Y., Xia, C., & Chen, W. (2022). Burden of liver cancer: From epidemiology to prevention. *Chinese Journal of Cancer Research*, 34(3), 554–566. <https://doi.org/10.21147/j.issn.1000-9604.2022.06.02>
- Liao, C. Y., Lee, C. Y., Wei, C. Y., Chao, Y., Huang, Y. H., Hou, M. C., Su, Y. H., Wu, J. C., & Su, C. W. (2022). Differential prognoses among male and female patients with hepatocellular carcinoma. *Journal of the Chinese Medical Association*, 85(5), 554–565. <https://doi.org/10.1097/JCMA.0000000000000722>
- Liou, W. L., Tan, T. J. Y., Chen, K., Goh, G. B. B., Chang, J. P. E., & Tan, C. K. (2023). Gender survival differences in hepatocellular carcinoma: Is it all due to adherence to surveillance? A study of 1716 patients over three decades. *JGH Open*, 7(5), 377–386. <https://doi.org/10.1002/jgh3.12910>
- Lou, X. L., Sun, J., Gong, S. Q., Yu, X. F., Gong, R., & Deng, H. (2015). Interaction between circulating cancer cells and platelets: Clinical implication. *Chinese Journal of Cancer Research*, 27(5), 450–460.

- <https://doi.org/10.3978/j.issn.1000-9604.2015.04.10>
- McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of Hepatocellular Carcinoma. *Hepatology*, 73(S1), 4–13.  
<https://doi.org/10.1002/hep.31288>
- Mekuria, A. N., Routledge, M. N., Gong, Y. Y., & Sisay, M. (2020). *Aflatoxins as a risk factor for liver cirrhosis : a systematic review and meta-analysis*. 7, 1–8.
- Müller, L., Hahn, F., Auer, T. A., Fehrenbach, U., Gebauer, B., Haubold, J., Zensen, S., Kim, M. S., Eisenblätter, M., Diallo, T. D., Bettinger, D., Steinle, V., Chang, D. H., Zopfs, D., Pinto dos Santos, D., & Kloeckner, R. (2022). Tumor Burden in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: Head-to-Head Comparison of Current Scoring Systems. *Frontiers in Oncology*, 12(February), 1–9.  
<https://doi.org/10.3389/fonc.2022.850454>
- Noviyani, R. (2022). *Analisis Kesintasan Pasien Karsinoma Sel Hati Yang Menjalani Transarterial Chemoembolization Berdasarkan Kriteria Up To Seven RULLY NOVIYAN, Dr. dr. Nenang Ratnasari, SpPD, K-GEH ; dr. Catharina Triwikatmani, M.Kes, SpPD, K-GEH*. 22, 21–22.
- Ogunwobi, O. O., Harricharran, T., Huaman, J., Galuza, A., Odumuwagon, O., Tan, Y., Ma, G. X., & Nguyen, M. T. (2019). Mechanisms of hepatocellular carcinoma progression. *World Journal of Gastroenterology*, 25(19), 2279–2293. <https://doi.org/10.3748/wjg.v25.i19.2279>
- Pang, Q., Gong, X., Pan, H., Wang, Y., Hu, X., Liu, H., & Jin, H. (2024). Platelet count as a predictor of vascular invasion and extrahepatic metastasis in hepatocellular carcinoma: A systematic review and meta-analysis. *Heliyon*, 10(6), e28173. <https://doi.org/10.1016/j.heliyon.2024.e28173>
- Refolo, M. G., Messa, C., Guerra, V., Carr, B. I., & D'alessandro, R. (2020). Inflammatory mechanisms of hcc development. *Cancers*, 12(3).  
<https://doi.org/10.3390/cancers12030641>
- Rich, N. E., Murphy, C. C., Yopp, A. C., Tiro, J., Marrero, J. A., & Singal, A. G. (2020). Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma. *Alimentary Pharmacology and Therapeutics*, 52(4), 701–709. <https://doi.org/10.1111/apt.15917>
- Samant, H., Amiri, H. S., & Zibari, G. B. (2021). Addressing the worldwide hepatocellular carcinoma: Epidemiology, prevention and management. *Journal of Gastrointestinal Oncology*, 12(5), 361–373.  
<https://doi.org/10.21037/JGO.2020.02.08>
- Singal, A. G., Llovet, J. M., Yarroan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., & Kulik, L. M. (2023). *PRACTICE GUIDANCE AASLD Practice Guidance on prevention , diagnosis , and treatment of hepatocellular carcinoma* (Issue May).  
<https://doi.org/10.1097/HEP.0000000000000466>
- Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: A Cancer Journal for Clinicians*, 71(3), 209–249.

<https://doi.org/10.3322/caac.21660>

- Suresh, D., Srinivas, A. N., & Kumar, D. P. (2020). *Etiology of Hepatocellular Carcinoma : Special Focus on Fatty Liver Disease*. 10(November), 1–9. <https://doi.org/10.3389/fonc.2020.601710>
- Takagi, K., Buettner, S., & Ijzermans, J. N. M. (2020). Prognostic significance of the controlling nutritional status (CONUT) score in patients with colorectal cancer: A systematic review and meta-analysis. *International Journal of Surgery*, 78, 91–96. <https://doi.org/10.1016/j.ijso.2020.04.046>
- Takuma Nakatsuka and Ryosuke Tateishi. (2023). *Development and prognosis of hepatocellular carcinoma in patients with diabetes*. 29(1).
- Tejasaputra, C. (2023). *Platelet-to-lymphocyte ratio (PLR) sebagai indikator prognostik pasien karsinoma sel hati yang menjalani TACE*. 4(1), 1–23.
- Toshida, K., Itoh, S., Kayashima, H., Nagao, Y., Yoshiya, S., Tomino, T., Fujimoto, Y. K., Tsutsui, Y., Nakayama, Y., Harada, N., & Yoshizumi, T. (2023). The hemoglobin, albumin, lymphocyte, and platelet score is a prognostic factor for Child–Pugh A patients undergoing curative hepatic resection for single and small hepatocellular carcinoma. *Hepatology Research*, 53(6), 522–530. <https://doi.org/10.1111/hepr.13885>
- Tsilimigras, D. I., Mehta, R., Paredes, A. Z., Moris, D., Sahara, K., Bagante, F., Ratti, F., Marques, H. P., Silva, S., Soubrane, O., Lam, V., Poultsides, G. A., Popescu, I., Grigorie, R., Alexandrescu, S., Martel, G., Workneh, A., Guglielmi, A., Hugh, T., ... Pawlik, T. M. (2020). Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma beyond the Milan Criteria. *Annals of Surgery*, 272(4), 574–581. <https://doi.org/10.1097/SLA.0000000000004346>
- van Dijk, A. M., Coppens, B. J. P., van Beers, M. A., Bruins Slot, A. S., Verstraete, C. J. R., de Bruijne, J., Vleggaar, F. P., & van Erpecum, K. J. (2022). Nutritional status in patients with hepatocellular carcinoma: Potential relevance for clinical outcome. *European Journal of Internal Medicine*, 104(July), 80–88. <https://doi.org/10.1016/j.ejim.2022.07.002>
- Weinmann, A., Koch, S., Niederle, I. M., Schulze-bergkamen, H., Hoppe-lotichius, M., Otto, G., Schuchmann, M., Galle, P. R., & Wo, M. A. (2014). *Trends in Epidemiology , Treatment , and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009 An Analysis of 1066 Cases of a German HCC Registry*. 48(3), 279–289.
- Won, W., Lee, E. H., Gotina, L., Chun, H., Lee, J.-H., Park, U., Kim, D., Kim, T. Y., Choi, J., Kim, Y., Park, S. J., Bhalla, M., Lim, J., Park, J.-H., Oh, S.-J., Ryu, H., Pae, A. N., Park, K. D., & Lee, C. J. (2024). Hemoglobin as a peroxidase and drug target for oxidative stress-related diseases. *BioRxiv*, July, 2024.05.21.594979. <https://www.biorxiv.org/content/10.1101/2024.05.21.594979v2%0Ahttps://www.biorxiv.org/content/10.1101/2024.05.21.594979v2.abstract>
- Zhang, D., Chen, S., Cao, W., Geng, N., & Feng, C. (2023). HALP score based on hemoglobin, albumin, lymphocyte and platelet can predict the prognosis of tongue squamous cell carcinoma patients. *Heliyon*, 9(9), e20126. <https://doi.org/10.1016/j.heliyon.2023.e20126>

- Zhang, D., Zeng, H., Pan, Y., Zhao, Y., Wang, X., Chen, J., Wang, J., Zhang, Y., Zhou, Z., Xu, L., Chen, M., & Hu, D. (2022). Liver Tumor Markers, HALP Score, and NLR: Simple, Cost-Effective, Easily Accessible Indexes for Predicting Prognosis in ICC Patients after Surgery. *Journal of Personalized Medicine*, *12*(12), 1–15. <https://doi.org/10.3390/jpm12122041>
- Zhou, J., & Yang, D. (2023). Prognostic Significance of Hemoglobin, Albumin, Lymphocyte and Platelet (HALP) Score in Hepatocellular Carcinoma. *Journal of Hepatocellular Carcinoma*, *10*(May), 821–831. <https://doi.org/10.2147/JHC.S411521>